San Diego-based Tandem Diabetes, a developer of insulin pumps, has raised another $31.0M in funding, bring its current funding round to $52.3M, according to a regulatory filing by the firm lsat week. Source of the new funding was not disclosed by the company. Tandem has previously raised funding from Domain Associates, Second Technology Capital Investors, and TPG Ventures. $21.3M of the current funding round came in May. More information »